Min Zhao

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4990039/publications.pdf

Version: 2024-02-01

33	2,551	430754	501076
papers	citations	18 h-index	28 g-index

34	34	34	2461
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chronic Systemic Dexamethasone Regulates the Mineralocorticoid/Glucocorticoid Pathways Balance in Rat Ocular Tissues. International Journal of Molecular Sciences, 2022, 23, 1278.	1.8	8
2	Mineralocorticoid pathway in retinal health and diseases. British Journal of Pharmacology, 2022, 179, 3190-3204.	2.7	8
3	Meteorin Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration. Journal of Clinical Medicine, 2021, 10, 2973.	1.0	5
4	Mineralocorticoid Receptor Pathway and Its Antagonism in a Model of Diabetic Retinopathy. Diabetes, 2021, 70, 2668-2682.	0.3	14
5	Pathogenic Effects of Mineralocorticoid Pathway Activation in Retinal Pigment Epithelium. International Journal of Molecular Sciences, 2021, 22, 9618.	1.8	11
6	Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models. Molecular Vision, 2021, 27, 323-353.	1.1	1
7	Letter to the Editor From Behar-Cohen et al.: â€œThe Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathyâ€• Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	1
8	Multimodal Imaging-Based Central Serous Chorioretinopathy Classification. Ophthalmology Retina, 2020, 4, 1043-1046.	1.2	64
9	Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents. Experimental Eye Research, 2019, 187, 107747.	1.2	25
10	Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. Experimental Eye Research, 2019, 187, 107754.	1.2	25
11	Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. Nature Communications, 2019, 10, 369.	5.8	47
12	Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization. Drug Discovery Today, 2019, 24, 1436-1439.	3.2	4
13	Ocular biocompatibility of dexamethasone acetate loaded poly(É›-caprolactone) nanofibers. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 20-30.	2.0	36
14	Mechanisms of macular edema: Beyond the surface. Progress in Retinal and Eye Research, 2018, 63, 20-68.	7.3	422
15	Ocular safety of Intravitreal Clindamycin Hydrochloride Released by PLGA Implants. Pharmaceutical Research, 2017, 34, 1083-1092.	1.7	10
16	Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. Journal of Controlled Release, 2017, 266, 187-197.	4.8	29
17	Anti-Inflammatory Effect of Dexamethasone Controlled Released From Anterior Suprachoroidal Polyurethane Implants on Endotoxin-Induced Uveitis in Rats. , 2016, 57, 1671.		26
18	Bioactive Glass Nanoparticles-Loaded Poly(É›-caprolactone) Nanofiber as Substrate for ARPE-19 Cells. Journal of Nanomaterials, 2016, 2016, 1-12.	1.5	11

#	Article	IF	Citations
19	Corticosteroids and the retina. Current Opinion in Neurology, 2016, 29, 49-54.	1.8	29
20	SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2015, 35, 2505-2515.	1.0	116
21	Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in Retinal and Eye Research, 2015, 48, 82-118.	7.3	712
22	Choroidal Mast Cells in Retinal Pathology. American Journal of Pathology, 2015, 185, 2083-2095.	1.9	24
23	In vitro and in vivo ocular biocompatibility of electrospun poly(É›-caprolactone) nanofibers. European Journal of Pharmaceutical Sciences, 2015, 73, 9-19.	1.9	48
24	A New CRB1 Rat Mutation Links MÃ¼ller Glial Cells to Retinal Telangiectasia. Journal of Neuroscience, 2015, 35, 6093-6106.	1.7	54
25	Anti-vascular endothelial growth factor acts on retinal microglia/macrophage activation in a rat model of ocular inflammation. Molecular Vision, 2014, 20, 908-20.	1.1	27
26	MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2013, 33, 2096-2102.	1.0	188
27	Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. Journal of Clinical Investigation, 2012, 122, 2672-2679.	3.9	316
28	The Aldosterone-Mineralocorticoid Receptor Pathway Exerts Anti-Inflammatory Effects in Endotoxin-Induced Uveitis. PLoS ONE, 2012, 7, e49036.	1.1	30
29	Differential Regulations of AQP4 and Kir4.1 by Triamcinolone Acetonide and Dexamethasone in the Healthy and Inflamed Retina. , 2011, 52, 6340.		63
30	Endothelial Morphometry by Image Analysis of Corneas Organ Cultured at 31Â°C. , 2010, 51, 1356.		18
31	The neuroretina is a novel mineralocorticoid target: aldosterone upâ€regulates ion and water channels in MÃ¼ller glial cells. FASEB Journal, 2010, 24, 3405-3415.	0.2	129
32	Use of Poloxamers for Deswelling of Organ-Cultured Corneas. , 2008, 49, 550.		27
33	Comparison of Two Semiautomated Methods for Evaluating Endothelial Cells of Eye Bank Corneas. , 2007, 48, 3077.		23